The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...

Respiratory syncytial virus, or RSV, is a common respiratory virus that typically causes mild, cold-like symptoms. According to the Centers for Disease Control and Prevention (CDC), most people who ...

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making.

Guidelines recommend a single dose of RSV vaccine for older adults, but long-term data on the duration of protection is limited. In this study of U.S. veterans, effectiveness slid from over 80% in the ...

Patients aged 75 years or older who are not immunocompromised should receive a protein subunit respiratory syncytial virus (RSV) vaccine, according to new recommendations from the American College of ...

RSV vaccination for adults aged 60+ could prevent significant LRTD cases, hospitalizations, and deaths over five years. A 5-percentage-point increase in vaccine uptake could avert over 222,000 LRTD ...

FDA expansion of the Arexvy vaccine provides protection against RSV-related lower respiratory tract disease for at-risk adults aged 18 to 49 years. The Food and Drug Administration (FDA) has expanded ...